ALCON LABORATORIES (U.K.) LIMITED


ALCON LABORATORIES (U.K.) LIMITED

Company Registration Number:
00968373 (England and Wales)

Unaudited statutory accounts for the year ended 31 December 2022

Period of accounts

Start date: 1 January 2022

End date: 31 December 2022

ALCON LABORATORIES (U.K.) LIMITED

Contents of the Financial Statements

for the Period Ended 31 December 2022

Directors report
Profit and loss
Balance sheet
Additional notes
Balance sheet notes

ALCON LABORATORIES (U.K.) LIMITED

Directors' report period ended 31 December 2022

The directors present their report with the financial statements of the company for the period ended 31 December 2022

Principal activities of the company

The principal activity of the Company is to hold a loan with Alcon Eye Care UK Ltd.As set out in Note 1, the wider group is in the process of restructuring. Following this the Directorsmade the decision to wind up the company in 2020. This was due to take place throughout 2023however due to an internal restructuring, the decision was made to postpone the initiation of theliquidation process until 2024. The timing of the liquidation is currently uncertain but is expectedwithin 2 years of the signing date of the financial statements. As a result, these financialstatements have been prepared on a basis other than going concern.

Additional information

Business reviewThe Company is a private company limited by shares, domiciled and incorporated in England,United Kingdom.The profit for the financial year amounts to £212k (2021: £107k).Total shareholders’ funds for the financial year 2022 were £11,683k (2021: £11,471k).Future outlookThe Company is expected to be wound up within the next 2 years after the signing date of thefinancial statements. Due to internal restructuring in the finance department, it was decided toput on hold the project until early 2024.Financial risk management objectives and policies - Liquidity riskGiven the fact that the Company will be liquidated in the near future there are not considered tobe any significant financial risks. The Company will source additional funding from its immediateparent company where required to facilitate the liquidation.



Directors

The directors shown below have held office during the whole of the period from
1 January 2022 to 31 December 2022

Xavier Romeu
Mike Turner
Roy Henry


Secretary Rebecca Weston

The above report has been prepared in accordance with the special provisions in part 15 of the Companies Act 2006

This report was approved by the board of directors on
25 May 2023

And signed on behalf of the board by:
Name: Xavier Romeu
Status: Director

ALCON LABORATORIES (U.K.) LIMITED

Profit And Loss Account

for the Period Ended 31 December 2022

2022 2021


£

£
Administrative expenses: ( 36 ) ( 38 )
Operating profit(or loss): (36) (38)
Interest receivable and similar income: 248 146
Profit(or loss) before tax: 212 108
Tax: ( 1 )
Profit(or loss) for the financial year: 212 107

ALCON LABORATORIES (U.K.) LIMITED

Balance sheet

As at 31 December 2022

Notes 2022 2021


£

£
Current assets
Debtors: 3 10,000 10,000
Cash at bank and in hand: 1,718 1,501
Total current assets: 11,718 11,501
Creditors: amounts falling due within one year: 4 ( 35 ) ( 30 )
Net current assets (liabilities): 11,683 11,471
Total assets less current liabilities: 11,683 11,471
Total net assets (liabilities): 11,683 11,471
Capital and reserves
Called up share capital: 9,100 9,100
Profit and loss account: 2,583 2,371
Total Shareholders' funds: 11,683 11,471

The notes form part of these financial statements

ALCON LABORATORIES (U.K.) LIMITED

Balance sheet statements

For the year ending 31 December 2022 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

This report was approved by the board of directors on 25 May 2023
and signed on behalf of the board by:

Name: Xavier Romeu
Status: Director

The notes form part of these financial statements

ALCON LABORATORIES (U.K.) LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2022

  • 1. Accounting policies

    Basis of measurement and preparation

    These financial statements have been prepared in accordance with the provisions of Financial Reporting Standard 101

    Other accounting policies

    Going ConcernIn 2020, the Directors have made the decision to wind up of the Company and accordingly thesefinancial statements have not been prepared on the going concern basis. As a result, all assetsand liabilities which are not expected to be realized have been written off.Interest incomeInterest income is recognised using the effective interest method. When a loan and receivable isimpaired, the Company reduces the carrying amount to its recoverable amount, being theEstimated future cash flow discounted at the original effective interest rate of the instrument,and continues unwinding the discount as interest income.TaxationTax is recognised in the income statement. The current income tax charge is calculated on thebasis of the tax laws enacted or substantively enacted at the balance sheet date in the countrieswhere the Company operates and generates taxable income. Management periodically evaluatespositions taken in tax returns with respect to situations in which applicable tax regulation issubject to interpretation. It establishes provisions where appropriate on the basis of amountsexpected to be paid to the tax authorities.DebtorsDebtors are amounts due from related parties for services performed in the ordinary course ofbusiness. If collection is expected in one year or less (or in the normal operating cycle of thebusiness if longer), they are classified as current assets. If not, they are presented as non-currentassets. Debtors are recognised initially at fair value and subsequently measured at amortised costusing the effective interest method, less provision for impairment.A number of new or amendments became applicable for the current reporting period. The impactof the adoption of the new amendments and the new accounting policies are disclosed below.The amendments to IFRS 9 and IAS 39 Financial Instruments: Recognition and Measurementprovide a number of reliefs, which apply to all loans that are directly affected by interest ratebenchmark reform. When changing the basis for determining contractual cash flows for financialassets and liabilities (including lease liabilities), the reliefs have the effect that the changes, thatare necessary as a direct consequence of IBOR reform and which are considered economicallyequivalent, will not result in an immediate gain or loss in the income statement. The company hasassessed the transition to alternative benchmark rates.Starting from the last contract amendment in 2022, TISONI1Y Sterling Libor rate was applied andthis amendment had no material impact on the company’s financial statements but increasinginterest income.CreditorsCreditors are obligations to pay for goods or services that have been acquired in the ordinarycourse of business from suppliers. Creditors are recognised initially at fair value and subsequentlymeasured at amortised cost using the effective interest method.Cash at bank and in handCash at bank and in hand comprise deposits with banks and bank and cash balances. In thebalance sheet, bank overdrafts are included in borrowings in current liabilities.Critical accounting estimates and judgmentsThe Company did not make any significant judgments and estimates on applying accountingpolicies during the financial year ended 31st December 2022 or 31st December 2021.

ALCON LABORATORIES (U.K.) LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2022

  • 2. Employees

    2022 2021
    Average number of employees during the period 0 0

ALCON LABORATORIES (U.K.) LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2022

3. Debtors

2022 2021
£ £
Other debtors 10,000 10,000
Total 10,000 10,000

ALCON LABORATORIES (U.K.) LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2022

4. Creditors: amounts falling due within one year note

2022 2021
£ £
Trade creditors 35 30
Total 35 30